Ranitidine and Acid Suppression in Neonates

Introduction to Risks and Alternatives

The American Academy of Pediatrics recommends that acid suppressive therapy, including H2 antagonists and PPIs, should not be used as first-line treatment for neonatal GERD symptoms without attempting dietary modification first, due to increased risks of necrotizing enterocolitis, community-acquired pneumonia, gastroenteritis, and candidemia 3
Ranitidine and other H2 antagonists have limited long-term efficacy due to tachyphylaxis developing within 6 weeks of use, and carry risks of liver disease and gynecomastia in pediatric patients 1, 2

Acid suppression in neonates significantly increases the risk of necrotizing enterocolitis in preterm infants, community-acquired pneumonia, gastroenteritis, and candidemia 1, 2, 4
The American Academy of Pediatrics suggests that PPIs are preferred over H2 antagonists if acid suppression is deemed necessary, as they are more potent and don't develop tachyphylaxis 1, 2

The American Academy of Pediatrics recommends starting with parental reassurance and education, and implementing feeding modifications such as reducing feeding volume, increasing feeding frequency, and keeping the infant upright or prone when awake and under supervision 1, 2, 3
For breastfed infants, a trial of a 2-4 week maternal exclusion diet eliminating at least milk and egg is recommended, while for formula-fed infants, switching to extensively hydrolyzed protein or amino acid-based formula for 2-4 weeks is suggested 1, 3

The American Academy of Pediatrics advises against empirically starting acid suppression without first attempting dietary modification, as this represents overprescription of potentially harmful medications when safer alternatives exist 3
The use of prokinetic agents such as metoclopramide and domperidone is not recommended due to insufficient evidence and significant adverse effects including extrapyramidal reactions 1, 2, 4